RT Journal Article
SR Electronic
T1 Automated Detection of Candidate Subjects with Cerebral Microbleeds using Machine Learning
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.21.21263298
DO 10.1101/2021.09.21.21263298
A1 Sundaresan, Vaanathi
A1 Arthofer, Christoph
A1 Zamboni, Giovanna
A1 Dineen, Robert A.
A1 Rothwell, Peter M.
A1 Sotiropoulos, Stamatios N.
A1 Auer, Dorothee P.
A1 Tozer, Daniel
A1 Markus, Hugh S.
A1 Miller, Karla L.
A1 Dragonu, Iulius
A1 Sprigg, Nikola
A1 Alfaro-Almagro, Fidel
A1 Jenkinson, Mark
A1 Griffanti, Ludovica
YR 2021
UL http://medrxiv.org/content/early/2021/09/23/2021.09.21.21263298.abstract
AB Cerebral microbleeds (CMBs) appear as small, circular, well defined hypointense lesions of a few mm in size on T2*-weighted gradient recalled echo (T2*-GRE) images and appear enhanced on susceptibility weighted images (SWI). Due to their small size, contrast variations and other mimics (e.g. blood vessels), CMBs are highly challenging to detect automatically. In large datasets (e.g. the UK Biobank dataset), exhaustively labelling CMBs manually is difficult and time consuming. Hence it would be useful to preselect candidate CMB subjects in order to focus on those for manual labelling, which is essential for training and testing automated CMB detection tools on these datasets. In this work, we aim to detect CMB candidate subjects from a larger dataset, UK Biobank, using a machine learning-based, computationally light pipeline. For our evaluation, we used 3 different datasets, with different intensity characteristics, acquired with different scanners. They include the UK Biobank dataset and two clinical datasets with different pathological conditions. We developed and evaluated our pipelines on different types of images, consisting of SWI or GRE images. We also used the UK Biobank dataset to compare our approach with alternative CMB preselection methods using non-imaging factors and/or imaging data. Finally, we evaluated the pipeline’s generalisability across datasets. Our method provided subject-level detection accuracy > 80% on all the datasets (withindataset results), and showed good generalisability across datasets, providing a consistent accuracy of over 80%, even when evaluated across different modalities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded in part by the Wellcome Trust [203139/Z/16/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. This work was also supported by the Engineering and Physical Sciences Research Council (EPSRC), Medical Research Council (MRC) [grant number EP/L016052/1], NIHR Nottingham Biomedical Research Centre and Wellcome Centre for Integrative Neuroimaging, which has core funding from the Wellcome Trust. The computational aspects of this research were funded from National Institute for Health Research (NIHR) Oxford BRC with additional support from the Wellcome Trust Core Award Grant Number 203141/Z/16/Z. The Oxford Vascular Study is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Wellcome Trust, Wolfson Foundation, the British Heart Foundation and the European Unions Horizon 2020 programme (grant 666881, SVDs[at]target). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The TICH-2 MRI substudy was funded by a grant from British Heart Foundation (grant reference PG/14/96/31262) and the TICH-2 trial was funded by a grant from the UK National Institute for Health Research Health Technology Assessment programme (project code 11_129_109). VS is supported by the Wellcome Centre for Integrative Neuroimaging. CA was supported by NIHR Nottingham Biomedical Research Centre and is now supported by Wellcome Trust Collaborative Award [215573/Z/19/Z]. GZ is supported by the Italian Ministry of Education (MIUR) and by a grant Dipartimenti di eccellenza 2018-2022, MIUR, Italy, to the Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia. PMR and HSM are in receipt of NIHR Senior Investigator awards. KM is funded by a Senior Research Fellowship from the Wellcome Trust (202788/Z/16/Z). MJ is supported by the NIHR Oxford Biomedical Research Centre (BRC). LG is supported by the Oxford Parkinsons Disease Centre (Parkinsons UK Monument Discovery Award, J-1403), the MRC Dementias Platform UK (MR/L023784/2), and the National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:OXVASC was approved by the South Central - Oxford A Research Ethics Committee (Research Ethics Committee reference number: 05/Q1604/70). Written informed consent was obtained from all participants. Human subjects: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) to obtain and disseminate data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/), and these ethical regulations cover the work in this study. Written informed consent was obtained from all participants. The TICH-2 trial obtained ethical approval from East Midlands (Nottingham 2) NHS Research Ethics Committee (Reference: 12/EM/0369) and the amendment to allow the TICH2 MRI sub-study was approved in April 2015 (amendment number SA02/15).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for data from the OXVASC Study will be considered by P.M.R. in line with data protection laws. The TICH2 MRI substudy data can be shared with bonafide researchers and research groups on written request to the substudy PI Prof Rob Dineen. Proposals will be assessed by the PI with advice from the trial TICH2 Steering Committee if required and a Data Transfer Agreement will established before any data are shared. The UK Biobank datasets are available to researchers through an open application via https://www.ukbiobank.ac.uk/register-apply/.